Holen Sie sich die Stockscreener-App
13.80
0.00%
0.00
Handel nachbörslich:
13.80
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Using data tools to time your Theravance Biopharma Inc. exitQuarterly Portfolio Summary & Smart Allocation Stock Tips - Newser
Is Theravance Biopharma Inc. trending in predictive chart modelsJuly 2025 Outlook & Fast Entry and Exit Trade Plans - Newser
Visualizing Theravance Biopharma Inc. stock with heatmapsJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Risk vs reward if holding onto Theravance Biopharma Inc.Earnings Miss & Real-Time Volume Analysis Alerts - Newser
What moving averages say about Theravance Biopharma Inc.July 2025 EndofMonth & Real-Time Stock Movement Alerts - Newser
Best data tools to analyze Theravance Biopharma Inc. stockMarket Risk Analysis & Long-Term Safe Investment Plans - Newser
Is Theravance Biopharma Inc. stock a good hedge against inflationPortfolio Performance Summary & Fast Entry High Yield Tips - Newser
Automated trading signals detected on Theravance Biopharma Inc.Trade Exit Report & Fast Exit Strategy with Risk Control - Newser
Theravance Biopharma stock rating reiterated at Buy by BTIG - Investing.com Nigeria
Theravance Completes Enrollment in Phase 3 CYPRESS Study - MSN
Viatris Inc. shares fall 1.13% intraday as Theravance Biopharma completes enrollment in pivotal Phase 3 trial. - AInvest
Published on: 2025-08-25 06:51:25 - Newser
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy - PR Newswire
Earnings visualization tools for Theravance Biopharma Inc.Trade Exit Summary & High Return Trade Opportunity Guides - Newser
Is Theravance Biopharma Inc. still worth holding after the dipCEO Change & Consistent Profit Trade Alerts - Newser
Using data models to predict Theravance Biopharma Inc. stock movement2025 Key Lessons & Free Accurate Trade Setup Notifications - Newser
What are the future prospects of Theravance Biopharma Inc.Chart Signals & Growth Focused Stock Pick Reports - theviewers.co.kr
Will Breakout in Theravance Biopharma Inc. Sustain Through Next WeekWeekly Trade Report & AI Optimized Trade Strategies - beatles.ru
Bull Run: Can Theravance Biopharma Inc. be recession proofJuly 2025 Price Swings & Stepwise Swing Trade Plans - theviewers.co.kr
Theravance Biopharma Inc. Stock Recovery Path — Analyst Breakdown2025 Market Sentiment & AI Driven Price Forecasts - 더경남뉴스
Theravance Biopharma Maintains Buy Rating and $26 Price Target - AInvest
Theravance Biopharma shares fall 1.05% after-hours following settlement with Cipla. - AInvest
Theravance Biopharma Settles Patent Dispute with Cipla - TipRanks
Theravance Biopharma reaches patent settlement with Cipla on YUPELRI inhalation - Investing.com
Using RSI to spot recovery in Theravance Biopharma Inc.New Guidance & Safe Entry Point Alerts - Newser
What’s the recovery path for long term holders of Theravance Biopharma Inc.July 2025 Summary & Real-Time Volume Analysis Alerts - Newser
Does Theravance Biopharma Inc. qualify in momentum factor screeningJuly 2025 Rallies & Verified Entry Point Detection - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedWeekly Market Outlook & High Accuracy Buy Signal Tips - Newser
Is Theravance Biopharma Inc. a momentum stock2025 Winners & Losers & Daily Technical Stock Forecast Reports - classian.co.kr
What earnings revisions data tells us about Theravance Biopharma Inc.2025 Volatility Report & AI Powered Buy/Sell Recommendations - Newser
Using Ichimoku Cloud for Theravance Biopharma Inc. technicals2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Theravance Biopharma Inc. stock undervalued right now2025 Market WrapUp & Low Risk Entry Point Tips - classian.co.kr
Tools to monitor Theravance Biopharma Inc. recovery probabilityJuly 2025 Action & Daily Profit Focused Stock Screening - Newser
How Theravance Biopharma Inc. stock performs during market volatilityJuly 2025 Setups & High Accuracy Investment Signals - Newser
Candlestick Signal Suggests Reversal in Theravance Biopharma Inc.2025 Volume Leaders & Real-Time Volume Analysis Alerts - metal.it
Leerink Partners Reaffirms Their Hold Rating on Theravance Biopharma (TBPH) - The Globe and Mail
Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen - Defense World
What institutional flow reveals about Theravance Biopharma Inc.Weekly Investment Summary & Consistent Income Trade Ideas - Newser
Real time social sentiment graph for Theravance Biopharma Inc.2025 Top Decliners & AI Driven Price Predictions - Newser
Candlestick Reversal Detected on Theravance Biopharma Inc.’s ChartJuly 2025 Fed Impact & Reliable Volume Spike Alerts - metal.it
What makes Theravance Biopharma Inc. stock price move sharplyJuly 2025 Snapshot & Short-Term Trading Opportunity Alerts - thegnnews.com
H.C. Wainwright Maintains Buy Rating for Theravance Biopharma with $15 Price Target - AInvest
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
H.C. Wainwright Sticks to Their Buy Rating for Theravance Biopharma (TBPH) - The Globe and Mail
The 11% Return This Week Takes Theravance Biopharma's (NASDAQ:TBPH) Shareholders One-year Gains to 51% - 富途牛牛
Theravance Biopharma Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Theravance Biopharma (NASDAQ:TBPH) shareholder returns have been respectable, earning 51% in 1 year - simplywall.st
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Purchased by XTX Topco Ltd - Defense World
Theravance Biopharma’s Earnings Call Highlights Strategic Gains - TipRanks
Theravance Biopharma, Inc. SEC 10-Q Report - TradingView
0.98%
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):